Key clinical point: The findings could inform patient management to reduce progression to persistent headache.
Major finding: Heightened risk was associated with migraine history (relative risk, 2.4), previous head injury (odds ratio, 5.8), medication overuse (RR, 2.6) and psychological history (OR, 5).
Study details: A retrospective analysis of 300 patients.
Disclosures: The study did not receive any funding. Dr. Chan had no relevant financial disclosures. Dr. Charles consults for consults for Amgen, BioHaven, Eli Lilly, Novartis, and Lundbeck.
Chan T et al. AHS 2020.